The U.S. Food and Drug Administration (FDA) awarded a firm-fixed-price purchase order contract valued at $142,010 to Cenmed Enterprises Inc., a self-certified small disadvantaged business, to provide a Targeted Desorption Electrospray Ionization Mass Spectrometry Imaging (DESI-MSI) instrument. The contract, which has an ultimate completion date of October 23, 2025, was awarded on September 24, 2024 and is not set aside. Cenmed, a manufacturer of medical supplies based in New Brunswick, New Jersey, will deliver the DESI-MSI instrument to support the FDA's Office of Applied Research and Safety Assessment's mission to ensure produce safety and establish an emerging chemicals of concern program.
Generated 9/25/24, 9:22 AM